Table 1.
Correlation of TPX2 expression with clinicopathologic features
| Characteristics | Total (n = 106) | TPX2 | P value | |
|---|---|---|---|---|
| Negative (n = 35) | Positive (n = 71) | |||
| Gender | ||||
| Male | 67 (63.2 %) | 22 (32.8 %) | 45 (67.2 %) | 0.958 |
| Female | 39 (36.8 %) | 13 (33.3 %) | 26 (66.7 %) | |
| Age (years) | ||||
| ≥60 | 46 (43.4 %) | 7 (15.2 %) | 39 (84.8 %) | 0.001 |
| <60 | 60 (56.6 %) | 28 (46.7 %) | 32 (53.3 %) | |
| T stage | ||||
| 1 | 10 (9.4 %) | 8 (80 %) | 2 (20 %) | 0.003 |
| 2 | 10 (9.4 %) | 4 (40 %) | 6 (60 %) | |
| 3 | 84 (79.2 %) | 22 (26.2 %) | 62 (73.8 %) | |
| 4a | 2 (1.9 %) | 1 (50 %) | 1 (50 %) | |
| N stage | ||||
| 0 | 21 (19.8 %) | 10 (47.6 %) | 11 (35.2 %) | 0.120 |
| 1 | 38 (35.8 %) | 14 (36.8 %) | 24 (63.2 %) | |
| 3 | 47 (44.3 %) | 11 (6.3 %) | 36 (3.6 %) | |
| M stage | ||||
| 0 | 99 (93.4 %) | 34 (34.3 %) | 65 (65.7 %) | 0.421 |
| 1 | 7 (6.6 %) | 1 (14.3 %) | 6 (85.7 %) | |
| TNM stage | ||||
| I | 13 (12.3 %) | 5 (38.5 %) | 8 (61.5 %) | 0.144 |
| II | 17 (16.0 %) | 8 (47.1 %) | 9 (52.9 %) | |
| III | 69 (65.1 %) | 22 (31.9 %) | 47 (68.1 %) | |
| IV | 7 (6.3 %) | 0 (0 %) | 7 (100 %) | |
| Tumor size (cm) | ||||
| ≥5 | 74 (69.8 %) | 24 (32.4 %) | 50 (67.6 %) | 1.000 |
| <5 | 32 (30.2 %) | 11 (34.4 %) | 21 (65.6 %) | |
The results of immune-histochemical score were determined by the average score that given by two pathologists, immune-reactivities were scored by the intensity of staining (0, no staining; 1 weak = light yellow; 2 moderate = yellow brown; 3 strong = brown) and the percentage of stained cells (0 no staining; 1, 0–10 %; 2, 11–30 %; 3, 31–70 %; 4, >71 %). By multiplication of both values, a final score ranging between 0 and 12 was obtained. TPX2 over-expression was defined as final score more than zero